UNSPSC 51285316: Nifuroxime

This classification denotes an anti-infective agent with the molecular formula C5H4N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 465N7P5U85, chemically known as 2-furancarboxaldehyde, 5-nitro-, oxime, (z)- but more generally known as nifuroxime, which bears US NIH Compound Identifier 22601. European Medicines Agency schedules Nifuroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09272MIG.

UNSPSC 51285316 Nifuroxime is a Commodity code that in practice covers pharmaceutical products and medical supplies procured by state and local health agencies, emergency services, and cooperative purchasing alliances. The recent state and local opportunities tagged to this code show procurement of naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and medical and first aid supplies for fire department rescue operations. Issuing bodies include county health departments (Seminole County, Florida), city purchasing departments acting on behalf of emergency services (City of Tampa), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating state and local government facilities including Oregon). Scope of work ranges from specific pharmaceutical products with designated National Drug Codes and generic equivalents to emergency medical consumables such as respiratory equipment, cardiac monitoring electrodes, endotracheal tubes, bandaging materials, and oxygen delivery systems, with pricing models including fixed pricing, net price formats, and WAC-minus structures.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies with an estimated contract value of $700,000.00, designated as a sheltered-market opportunity exclusively for certified Small Local Business Enterprises (SLBEs) with a 5 percent bid discount; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness.